MD, FRCPC, FCAHS
Professor, BC Leadership Chair in Depression Research and Associate Head
University of British Columbia (UBC)
Director of the Mood Disorders Centre
Djavad Mowafaghian Centre for Brain Health
Vancouver, BC
Dr. Raymond W. Lam is Professor and BC Leadership Chair in Depression Research, and Associate Head, University of British Columbia (UBC) Department of Psychiatry. He is also Director of the Mood Disorders Centre at the Djavad Mowafaghian Centre for Brain Health in Vancouver. His research examines clinical and neurobiological factors in seasonal, treatment-resistant and workplace depression, biomarkers, clinical trials, and digital health technologies. He has published over 450 papers in peer-reviewed journals; Google Scholar lists over 27,000 citations to his work with an h-index of 88. Dr. Lam is also a lead investigator for the Canadian Biomarker Integration Network in Depression (CAN-BIND) and Executive Chair of the Asia-Pacific Economic Cooperative (APEC) Digital Hub for Mental Health, hosted at UBC. Dr. Lam has received many awards including Fellow, Canadian Academy of Health Sciences, one of the highest honours in the Canadian health sciences community, and recognition as a Clarivate’s Highly-Cited Researcher.
MD, CCFP, FCFP
Assistant Professor
Department of Family and Community Medicine
University of Toronto
Toronto (ON)
Dr. Jeffrey Habert is a Family Physician in Thornhill for the last 34 years. He is an Assistant Professor in the Dept. of Family and Community Medicine at the University of Toronto. He is also an Investigating Coroner for the City of Toronto
He is also Co-Editor of Canadian Primary Care Today
He is a member of Diabetes Canada: Dissemination & Implementation Committee.
He is currently one of the co-editors of the 2023 CANMAT MDD Guidelines.
Dr. Habert is a former Peer Assessor for the College of Physicians and Surgeons of Ontario (19 years)
He has an interest in the use of clinical practice guidelines, and has participated on committees to establish guidelines in the areas of Depression, Stroke, ASA in Primary Care and Thrombosis. He is the Previous co-chair of Thrombosis Canada Clinical Guides.
His clinical interests are varied, and include Diabetes, Obesity, Depression, ADHD, Insomnia, Thrombosis/Stroke and Osteoporosis.
He is also published in many of the above mentioned areas in addtion to others.
He is a National speaker in the multiple areas and actively participates on Scientific Committees involved in the creation of educational programs.
MD
Co-Director, Institute of Behavioral Science
Feinstein Institutes for Medical Research
Professor, Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, NY, USA
John Kane, MD served as Chair of Psychiatry at The Zucker Hillside Hospital for 34 years and Chair of Psychiatry at The Donald and Barbara Zucker School of Medicine for 12 years. He is Professor of Psychiatry and Molecular Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Co-Director of the Institute for Behavioral Science at the Feinstein Institutes for Medical Research.
He earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society, and the Schizophrenia International Research Society.
He has been a principal investigator on 23 National Institutes of Health (NIH) grants focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 940 peer-reviewed papers and has been consistently ranked by Thomson Reuters in the top 1% of researchers in his field, based on citations of his work. Dr. Kane has served on the Board of Scientific Counselors for the National Institute of Mental Health (NIMH), chaired the Psychopharmacologic Drugs Advisory Committee of the FDA, and serves on the editorial boards of numerous journals.
MD, FRCPC
Inpatient/Outpatient Psychiatrist
Oakville Hospital, ON
Vice President, Canadian Consortium for Early Intervention in Psychosis
Hamilton, ON
Associate Clinical Professor, McMaster University
Hamilton, ON
Dr. Hastings is an adult inpatient/outpatient psychiatrist at the Oakville Hospital, and Vice President of the Canadian Consortium for Early Intervention in Psychosis. He is an Associate Clinical Professor at McMaster University & a Lecturer at the University of Toronto .
MD, CM, MSc, FRCPC
Director, PEPP-MUHC (program for the evaluation and prevention of psychosis)
Director, Schizophrenia program, MUHC
Associate Professor, Department of Psychiatry, McGill University
Dr. Margolese is an Associate Professor in the Department of Psychiatry of McGill University. He is currently the program director of the McGill Clinical Pharmacology and Toxicology residency program. He is director of the PEPP first episode psychosis and Schizophrenia programs at the McGill University Health Centre and director of the Clinical Psychopharmacology and Therapeutics Unit.
He has given numerous lectures and presentations both nationally and internationally and has published over 75 articles. He is vice-president of research and a founding member of the Canadian Consortium for Early Intervention in Psychosis.
In his clinical work, Dr. Margolese specializes in psychopharmacology consultations, first episode psychosis, and treatment resistant schizophrenia.
Professor
Dr. Paul Janssen Chair in Psychotic Disorders
Director of Research, Department of Psychiatry, Dalhousie University
Clinical Director, Early Psychosis Intervention Nova Scotia
Nova Scotia Health
Dr. Tibbo received his B.Sc. (Hons) from Mount Alison University in Sackville, NB, and his MD from Memorial University of Newfoundland. He completed his residency in psychiatry at the University of Alberta and following this joined the staff at the University of Alberta Hospital as a clinician and researcher. He was instrumental in the development of and co-directed both the Bebensee Schizophrenia Research Unit and the Edmonton Early Psychosis Intervention Clinic.
In 2008 Dr. Tibbo was named the first Dr. Paul Janssen Chair in Psychotic Disorders, an endowed research chair, at Dalhousie University in Halifax NS. He is a Professor in the Department of Psychiatry with a cross-appointment in Psychology and Neuroscience at Dalhousie University. He is Director of Research for the Department of Psychiatry at Dalhousie and Clinical Director of the provincial Early Psychosis Intervention Nova Scotia (EPINS) program for Nova Scotia Health. Dr Tibbo is President of the Canadian Consortium for Early Intervention in Psychosis (CCEIP), helping to advance early intervention care at the national level.
Dr. Tibbo’s publications are primarily in the area of schizophrenia with his current foci of study including individuals at the early phase of, and at risk for, a psychotic illness. Dr. Tibbo’s areas of research include application of in vivo brain neuroimaging techniques to study psychosis as well as research interests in co-morbidities in schizophrenia (primarily substance misuse and psychosis), pathways to care/service delivery, education, and non-pharmacological treatment options. He is funded by local and national peer reviewed funding agencies and well published in leading journals. Dr Tibbo was a recipient of the Canadian Alliance on Mental Illness and Mental Health’s Champion of Mental Health Research award in 2017 and the 2018 Royal College of Physicians and Surgeons of Canada Prix d’Excellence - Specialist of the Year (region 5).
Dr. Atul Khullar is a psychiatrist and sleep specialist who focuses on the integrative management of obesity, sleep, mood/anxiety and attention deficit disorders in age groups from adolescence onwards. Recently, he has gained expertise in the selective use of ketamine for resistant mood disorders.
He completed his medical school and residency at the University of Alberta, and a sleep and mood/anxiety disorders fellowship at the University of Toronto. He has additional pediatric sleep medicine training from the University of Pennsylvania.
Dr. Khullar is board-certified in Psychiatry and Sleep Medicine in both Canada and the United States. He is also a fellow of the American Academy of Sleep Medicine, Diplomate of the American Board of Obesity Medicine, and a Clinical Associate Professor at the University of Alberta.
Actively involved in research and education, Dr. Khullar has given more than 600 invited presentations to public and professional audiences worldwide. He has published a number of articles and chapters as well as chaired more than 20 national CME programs in his specialized areas.
Currently, he is the medical director of the Northern Alberta Sleep Clinic in Edmonton. Dr. Khullar is also a senior consultant for the Grey Nuns Hospital, the Edmonton Oilers, the Newly Institute and MedSleep, a Canada-wide network of community sleep clinics. He has also worked with the Canadian Winter Olympic team in the past.
Professor of Neurology, Department of Clinical Neurological Sciences
Western University, London, Ontario
Received MD from Western University, where I also did training in Internal Medicine and Neurology, receiving my fellowship in Neurology from the Royal College of Physicians and Surgeons of Canada.
I did a Medical Research Council of Canada sponsored research fellowship with Professor Joseph Martin at Harvard Medical School and the Massachusetts General Hospital in Boston and then returned to Western University in London Ontario.
Professor of Neurology in the Department of Clinical Neurological Sciences.
After doing General Neurology with a special interest in Neuroendocrinology for 39 years, I now limit my practice to headache Neurology.
MBBS, FRCPC
Director, UBC Headache Clinic
Associate Clinical Professor, Neurology
University of British Columbia
Dr. Spacey is a Neurologist and Clinical Associate Professor in the Division of Neurology at UBC. She completed a residency in Neurology at UBC and a fellowship in Neurogenetics at Queen Square, London England. She is Director of the UBC Headache Clinic and UBC Neurogenetics Clinic. She is past president of the Canadian Headache Society and Director of the UBC Clinician Investigator Program. She lectures nationally and internationally. Her research interest and publications are in the field of calcium channels and the pathogenesis and molecular genetics of migraine.
BSc MSc MD FRCPC, Pain Psychiatrist
Clinical Assistant Professor, University of British Columbia
Director, UBC Pain Medicine Residency Program
Dr. Michael Butterfield is a Clinical Assistant Professor at UBC with appointments in the Departments of Psychiatry and Anesthesiology, Pharmacology & Therapeutics. He has a keen interest in medical education and has been the Director of the UBC Pain Medicine Residency Program for 5 years. He practices clinically at various tertiary pain clinics and the UBC Headache Clinic. He is a member of several national committees in the areas of pain medicine and psychiatry and was recently awarded the Early Career Achievement in Psychiatry Award by the Canadian Psychiatric Association.
Message